View all Webinars

Schwegman Lundberg & Woessner

Close     Close Mobile Menu

Categories

Recent

New ChIPs Chapter Offers Opportunities for Twin Cities Women
Twin Cities women in technology, law and policy now have...
Schwegman Named in Top 25 Firms for Minority Attorneys
Schwegman Lundberg & Woessner is pleased to have been recognized...
2019 IAM Strategy 300
We are proud to announce that attorneys Russ Slifer, Timothy...
Innovation & Automation in the IP Law Firm
Today, we are all hearing about artificial intelligence’s impact on...
Third Annual AIPLA Diversity in IP Happy Hour Events
Schwegman hosted the Minneapolis and San Jose editions of the...
AUTM Central Region Meeting
The 2019 AUTM Central Meeting will be held at the...

Fairchild (Taiwan) Corp. v. Power Integrations, Inc.

In my last post, I discussed estoppel in the context in inter partes review, in which defendant filed for IPR after losing in the courts. The Board found the claims-in-suit to be obvious. The Federal Circuit affirmed that the courts and the PTAB could reach different conclusions about patentability.

In Fairchild (Appeal no. 17-1002 (Fed. Cir., April 21, 2017)), the Federal Circuit found the asserted claims to be valid. Power Integrations had earlier filed for inter partes reexamination, using the same references it used in the District Court suit. The Federal Circuit ordered the PTAB to vacate and dismiss the reexamination of the claims found to be valid. Note that this decision rests on the provisions of 35 USC s. 317, which prevents a defendant that lost on invalidity in the courts from bringing the same challenge via inter partes reexamination. Section 317 (pre-AIA) is worded differently than Section 315(e)(2), relating to inter partes review estoppel. Post-AIA, defendant can lose at the district court but faces broad estoppel if it pursues IPR –although, (as in Novartis v. Noven) it can still prevail even if the records are identical (!) My head hurts!

 

This post is from the biotechnology patent law blog www.patents4Life.com.

  Back to All News